BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36753059)

  • 21. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.
    Kansal R; Quintanilla-Martinez L; Datta V; Lopategui J; Garshfield G; Nathwani BN
    Genes Chromosomes Cancer; 2013 Jan; 52(1):99-106. PubMed ID: 22996177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma.
    Techavichit P; Sosothikul D; Chaichana T; Teerapakpinyo C; Thorner PS; Shuangshoti S
    Hum Pathol; 2017 Nov; 69():118-122. PubMed ID: 28504206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review.
    A Al Hamad M; Albisher HM; Al Saeed WR; Almumtin AT; Allabbad FM; A Shawarby M
    BMC Cancer; 2019 Feb; 19(1):170. PubMed ID: 30795755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Localized Langerhans cell histiocytosis of the thymus with BRAF V600E mutation: a case report with immunohistochemical and genetic analyses.
    Oishi N; Kondo T; Mochizuki K; Inoue T; Kasai K; Nakazawa T; Mitsumori T; Katoh R
    Hum Pathol; 2014 Jun; 45(6):1302-5. PubMed ID: 24703101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
    Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
    J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
    Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
    Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
    Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
    Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pathophysiology and treatment of adult Langerhans cell histiocytosis].
    Tojo A; Kobayashi M
    Rinsho Ketsueki; 2020; 61(9):1028-1034. PubMed ID: 33162496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
    Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
    Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
    Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
    Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.
    Chakraborty R; Burke TM; Hampton OA; Zinn DJ; Lim KP; Abhyankar H; Scull B; Kumar V; Kakkar N; Wheeler DA; Roy A; Poulikakos PI; Merad M; McClain KL; Parsons DW; Allen CE
    Blood; 2016 Nov; 128(21):2533-2537. PubMed ID: 27729324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Primary intraosseous Rosai-Dorfman disease: a clinicopathological analysis of fourteen cases].
    Dong RF; Gong LH; Zhang W; Li L; Sun XQ; Zhang M; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2020 Sep; 49(9):904-909. PubMed ID: 32892555
    [No Abstract]   [Full Text] [Related]  

  • 38. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.
    Chang KTE; Tay AZE; Kuick CH; Chen H; Algar E; Taubenheim N; Campbell J; Mechinaud F; Campbell M; Super L; Chantranuwat C; Yuen ST; Chan JKC; Chow CW
    Mod Pathol; 2019 May; 32(5):598-608. PubMed ID: 30573850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis.
    Lonardi S; Scutera S; Licini S; Lorenzi L; Cesinaro AM; Gatta LB; Castagnoli C; Bollero D; Sparti R; Tomaselli M; Medicina D; Calzetti F; Cassatella MA; Facchetti F; Musso T; Vermi W
    Cancer Immunol Res; 2020 Jun; 8(6):829-841. PubMed ID: 32238382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
    Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
    Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.